The delayed presuturing method.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S István.
Explore the source record for details and available documents.
Ipriflavone is intensively metabolized by the organism, due to strong first-pass metabolism only a small fraction of the dose absorbed is unchanged Ipriflavone. Seven metabolites were identified in animal as well as in human studies. Ipriflavone is metabolized exclusively in the liver by elimination, or oxidation of the isopropyl group and hydroxylation of the beta-ring followed by conjugation with glucuronic and/or sulphuric acid. In animals 7-hydroxy-isoflavone (M1) was the main metabolite of Ipriflavone, while in man 7-(1-carboxy-ethoxy)-isofla-vone (M5). There was no sex-difference in the metabolism of Ipriflavone either in animal, or in human studies.
Ipriflavone administered to rats orally is well absorbed from small intestine via the portal route, distributed widely in tissues, metabolized extensively by oxidation, and eliminated from the body preferentially in urine. The absorption of ipriflavone is less effective in dogs, than in rats. In dogs, the compound absorbed is metabolized in the same way as in rats and the metabolites formed are eliminated largely in faeces, together with unabsorbed ipriflavone. In human, ipriflavone administered orally is rapidly absorbed, and quickly metabolized. The dose is eliminated mainly via the urinary route as metabolites (57% of the dose), and the smaller fraction with the faeces, mostly as ipriflavone (40% of the dose). There is no significant change in the pharmacokinetics of ipriflavone even after multiple dose. In the serum, ipriflavone and its metabolites are primarily bound to albumin, the binding is 94-99% and totally reversible.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The good results obtained with silicon implants used in the frontal region are reported by the authors. After the correct primary treatment the reconstructive operations have been performed at the least 6 months after the lesion, if the environment of the defect was free from any reaction during this time. 14 implantations have been performed in 2 years. Satisfactory functional and cosmetic results were obtained and the implant was to be removed in no case.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.